Literature DB >> 29755841

Quantitative PET of liver functions.

Susanne Keiding1,2, Michael Sørensen1,2, Kim Frisch1, Lars C Gormsen1, Ole Lajord Munk1.   

Abstract

Improved understanding of liver physiology and pathophysiology is urgently needed to assist the choice of new and upcoming therapeutic modalities for patients with liver diseases. In this review, we focus on functional PET of the liver: 1) Dynamic PET with 2-deoxy-2-[18F]fluoro-D-galactose (18F-FDGal) provides quantitative images of the hepatic metabolic clearance Kmet (mL blood/min/mL liver tissue) of regional and whole-liver hepatic metabolic function. Standard-uptake-value (SUV) from a static liver 18F-FDGal PET/CT scan can replace Kmet and is currently used clinically. 2) Dynamic liver PET/CT in humans with 11C-palmitate and with the conjugated bile acid tracer [N-methyl-11C]cholylsarcosine (11C-CSar) can distinguish between individual intrahepatic transport steps in hepatic lipid metabolism and in hepatic transport of bile acid from blood to bile, respectively, showing diagnostic potential for individual patients. 3) Standard compartment analysis of dynamic PET data can lead to physiological inconsistencies, such as a unidirectional hepatic clearance of tracer from blood (K1; mL blood/min/mL liver tissue) greater than the hepatic blood perfusion. We developed a new microvascular compartment model with more physiology, by including tracer uptake into the hepatocytes from the blood flowing through the sinusoids, backflux from hepatocytes into the sinusoidal blood, and re-uptake along the sinusoidal path. Dynamic PET data include information on liver physiology which cannot be extracted using a standard compartment model. In conclusion, SUV of non-invasive static PET with 18F-FDGal provides a clinically useful measurement of regional and whole-liver hepatic metabolic function. Secondly, assessment of individual intrahepatic transport steps is a notable feature of dynamic liver PET.

Entities:  

Keywords:  PET kinetics; bile acid PET; hepatic drug metabolism; hepatic galactose PET; hepatic glucose PET; hepatic palmitate PET; hepatobiliary excretion; liver PET; liver hemodynamics; liver metabolism

Year:  2018        PMID: 29755841      PMCID: PMC5944823     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  59 in total

1.  Synthesis and preliminary evaluation of (18)F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation.

Authors:  T R DeGrado; S Wang; J E Holden; R J Nickles; M Taylor; C K Stone
Journal:  Nucl Med Biol       Date:  2000-04       Impact factor: 2.408

2.  Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.

Authors:  Amalia Gastaldelli; Melania Gaggini; Giuseppe Daniele; Demetrio Ciociaro; Eugenio Cersosimo; Devjit Tripathy; Curtis Triplitt; Peter Fox; Nicolas Musi; Ralph DeFronzo; Patricia Iozzo
Journal:  Hepatology       Date:  2016-12       Impact factor: 17.425

3.  Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.

Authors:  Ronald Borra; Riika Lautamäki; Riita Parkkola; Markku Komu; Paul E Sijens; Kirsti Hällsten; Jörgen Bergman; Patricia Iozzo; Pirjo Nuutila
Journal:  Metabolism       Date:  2008-10       Impact factor: 8.694

4.  A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[18F]fluoro-2-deoxy-d-galactose.

Authors:  Mette Marie Fode; Kirstine Bak-Fredslund; Jørgen Baltzer Petersen; Esben Worm; Michael Sørensen; Morten Høyer
Journal:  Acta Oncol       Date:  2017-08-29       Impact factor: 4.089

5.  Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.

Authors:  Li Liu; Youwen Xu; Colleen Shea; Joanna S Fowler; Jacob M Hooker; Peter J Tonge
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

6.  Synthesis and evaluation of (18)F-labeled bile acid compound: a potential PET imaging agent for FXR-related diseases.

Authors:  Lina Jia; Dawei Jiang; Pengcheng Hu; Xiao Li; Hongcheng Shi; Dengfeng Cheng; Lan Zhang
Journal:  Nucl Med Biol       Date:  2014-04-01       Impact factor: 2.408

7.  Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET Study.

Authors:  Patricia Iozzo; Fabian Geisler; Vesa Oikonen; Maija Mäki; Teemu Takala; Olof Solin; Ele Ferrannini; Juhani Knuuti; Pirjo Nuutila
Journal:  J Nucl Med       Date:  2003-05       Impact factor: 10.057

8.  The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study.

Authors:  Peter Jepsen; Hendrik Vilstrup; Peter Ott; Susanne Keiding; Per K Andersen; Niels Tygstrup
Journal:  BMC Gastroenterol       Date:  2009-06-30       Impact factor: 3.067

9.  The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death.

Authors:  C Merkel; G Marchesini; A Fabbri; S Bianco; G Bianchi; E Enzo; D Sacerdoti; M Zoli; A Gatta
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

10.  Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxygalactose positron emission tomography.

Authors:  Michael Sørensen; Ole Lajord Munk; Frank Viborg Mortensen; Aage Kristian Olsen; Dirk Bender; Ludvik Bass; Susanne Keiding
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-15       Impact factor: 4.052

View more
  3 in total

1.  Hepatic regeneration following radiation-induced liver injury is associated with increased hepatobiliary secretion measured by PET in Göttingen minipigs.

Authors:  Kristoffer Kjærgaard; Britta Weber; Aage Kristian Olsen Alstrup; Jørgen Breede Baltzer Petersen; Rune Hansen; Stephen Jacques Hamilton-Dutoit; Frank Viborg Mortensen; Michael Sørensen
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

2.  Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography.

Authors:  Irene Hernández Lozano; Rudolf Karch; Martin Bauer; Matthias Blaickner; Akihiro Matsuda; Beatrix Wulkersdorfer; Marcus Hacker; Markus Zeitlinger; Oliver Langer
Journal:  AAPS J       Date:  2019-04-29       Impact factor: 4.009

Review 3.  Hepatic Positron Emission Tomography: Applications in Metabolism, Haemodynamics and Cancer.

Authors:  Miikka-Juhani Honka; Eleni Rebelos; Simona Malaspina; Pirjo Nuutila
Journal:  Metabolites       Date:  2022-04-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.